tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KALV Stock Latest News

Strong Initial Sales and Medical Endorsement Drive Buy Rating for KalVista Pharmaceuticals’ Ekterly
RatingsStrong Initial Sales and Medical Endorsement Drive Buy Rating for KalVista Pharmaceuticals’ Ekterly
6d ago
KALV
Promising Launch of Ekterly Boosts KalVista Pharmaceuticals’ Market Potential
PremiumRatings
Promising Launch of Ekterly Boosts KalVista Pharmaceuticals’ Market Potential
6d ago
KALV
KalVista price target raised to $28 from $27 at Citizens JMP
PremiumThe Fly
KalVista price target raised to $28 from $27 at Citizens JMP
6d ago
KALV
KalVista Pharmaceuticals Reports Strong Start for EKTERLY Launch
PremiumCompany Announcements
KalVista Pharmaceuticals Reports Strong Start for EKTERLY Launch
7d ago
KALV
Promising Market Penetration and Growth Potential for KalVista Pharmaceuticals’ Ekterly
PremiumRatings
Promising Market Penetration and Growth Potential for KalVista Pharmaceuticals’ Ekterly
7d ago
KALV
KalVista Pharmaceuticals’ Earnings Call Highlights EKTERLY Success
PremiumCompany AnnouncementsKalVista Pharmaceuticals’ Earnings Call Highlights EKTERLY Success
7d ago
KALV
Promising Outlook for KalVista Pharmaceuticals: Buy Rating Justified by Strong Launch Metrics and Strategic Initiatives for Ekterly
Premium
Ratings
Promising Outlook for KalVista Pharmaceuticals: Buy Rating Justified by Strong Launch Metrics and Strategic Initiatives for Ekterly
7d ago
KALV
Morning Movers: Kroger rises following second quarter results
Premium
The Fly
Morning Movers: Kroger rises following second quarter results
7d ago
KR
CNC
KalVista reports Q4 EPS ($1.12), consensus (96c)
PremiumThe Fly
KalVista reports Q4 EPS ($1.12), consensus (96c)
7d ago
KALV
Options Volatility and Implied Earnings Moves Today, September 11, 2025
PremiumMarket News
Options Volatility and Implied Earnings Moves Today, September 11, 2025
7d ago
KR
RH
Options Volatility and Implied Earnings Moves This Week, September 08 – September 11, 2025
PremiumMarket News
Options Volatility and Implied Earnings Moves This Week, September 08 – September 11, 2025
10d ago
KR
LE
KalVista Pharmaceuticals: A Promising Investment with Ekterly’s Market Potential
PremiumRatings
KalVista Pharmaceuticals: A Promising Investment with Ekterly’s Market Potential
15d ago
KALV
KALV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsKALV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
17d ago
KALV
KalVista Pharmaceuticals Updates Stockholder Meeting Schedule
Premium
Company Announcements
KalVista Pharmaceuticals Updates Stockholder Meeting Schedule
28d ago
8K
KALV
KalVista confirms maintenance of orphan designation for sebetralstat
Premium
The Fly
KalVista confirms maintenance of orphan designation for sebetralstat
1M ago
KALV
KalVista receives CHMP opinion recommending sebetralstat marketing authorization
PremiumThe Fly
KalVista receives CHMP opinion recommending sebetralstat marketing authorization
2M ago
KALV
Buy Rating for KalVista Pharmaceuticals: Strong Growth Potential Following Ekterly’s FDA Approval and Strategic Financial Positioning
PremiumRatings
Buy Rating for KalVista Pharmaceuticals: Strong Growth Potential Following Ekterly’s FDA Approval and Strategic Financial Positioning
2M ago
KALV
KalVista announces MHRA approval of Ekterly
PremiumThe Fly
KalVista announces MHRA approval of Ekterly
2M ago
KALV
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update
PremiumCompany Announcements
KalVista Pharmaceuticals: EKTERLY Launch and Financial Update
2M ago
KALV
KalVista Pharmaceuticals: Buy Rating Affirmed Amidst Promising Ekterly Launch and Strong Financial Position
PremiumRatingsKalVista Pharmaceuticals: Buy Rating Affirmed Amidst Promising Ekterly Launch and Strong Financial Position
2M ago
KALV
Buy Rating for KalVista Pharmaceuticals Amid Ekterly’s Market Launch and Insurance Challenges
Premium
Ratings
Buy Rating for KalVista Pharmaceuticals Amid Ekterly’s Market Launch and Insurance Challenges
2M ago
KALV
KalVista price target lowered to $27 from $30 at H.C. Wainwright
Premium
The Fly
KalVista price target lowered to $27 from $30 at H.C. Wainwright
2M ago
KALV

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >